Last reviewed · How we verify
Desogestrel-Ethinyl Estradiol 21 tablets
Desogestrel-ethinyl estradiol prevents ovulation by suppressing the luteinizing hormone surge through progestin and estrogen feedback on the hypothalamic-pituitary axis.
Desogestrel-ethinyl estradiol prevents ovulation by suppressing the luteinizing hormone surge through progestin and estrogen feedback on the hypothalamic-pituitary axis. Used for Contraception / prevention of pregnancy.
At a glance
| Generic name | Desogestrel-Ethinyl Estradiol 21 tablets |
|---|---|
| Also known as | Marvelon-21 |
| Sponsor | The Hospital for Sick Children |
| Drug class | Oral contraceptive |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception |
| Phase | Phase 3 |
Mechanism of action
This combination oral contraceptive contains a progestin (desogestrel) and an estrogen (ethinyl estradiol) that work synergistically to inhibit gonadotropin-releasing hormone and suppress follicle-stimulating hormone and luteinizing hormone secretion. By preventing the LH surge, ovulation is blocked, and the progestin also thickens cervical mucus and alters the endometrium to provide additional contraceptive efficacy.
Approved indications
- Contraception / prevention of pregnancy
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- Desogestrel-containing COCP Pharmacokinetic Validation Study (PHASE4)
- Assessing the Impact of Contraceptives on Bone Health Using 41Ca (PHASE4)
- Nonsurgical Management of Cesarean Scar Niche Related Abnormal Uterine Bleeding (NA)
- Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696) (PHASE4)
- A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021 (PHASE3)
- NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles (PHASE4)
- A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women (PHASE2)
- Comparative Trial in Hormone Withdrawal Associated Symptoms (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: